Prima BioMed to Present at ISBioTech Annual Meeting

Prima BioMed to Present at ISBioTech Annual Meeting 
SYDNEY, AUSTRALIA -- (Marketwire) -- 03/10/13 --  Prima BioMed Ltd
(ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," "the
Company") announces that its Vice President of Manufacturing, Marta
Schilling, will present at the 3rd annual meeting of the
International Society for BioProcess Technology (ISBioTech) to be
held in Rosslyn, Virginia.  
"The Challenges of Harmonizing cGMP Manufacturing Across Multiple
CMOs on Different Continents" will be delivered at 10:30am (local
time) on March 13, 2013. Ms. Schilling will present on the challenges
of harmonizing manufacturing for personalized immunocellular products
in multiple facilities in different regions. She will also review
Prima's accomplishments in the successful implementation of
harmonized manufacturing among the Company's three CVac manufacturing
facilities in Australia, the USA, and Germany.  
Ms. Schilling: "I am pleased to have been given the opportunity to
present at the ISBioTech conference. There is significant industry
interest in Prima's operational, logistical, and technical
accomplishments to support the consistent global manufacture of a
product like CVac."  
About Prima BioMed
 Prima BioMed is a globally active biotechnology
company. As a leader in personalized bio-therapeutic products for
cancer, Prima is dedicated to leveraging its current technology and
expertise to develop innovative treatment options for patients and to
maximize value to shareholders. Prima's lead product is CVac(TM), an
autologous dendritic cell product currently in clinical trials for
ovarian cancer patients who are in remission. 
For further information please contact: 
USA Investor/Media:
Ms. Jessica Brown
Prima BioMed Ltd. 
+1 (919) 710-9061  
Australia Investor/Media:
Mr. James Moses
Mandate Corporate 
+61 (0) 420 991 574  
Europe Investor/Media:
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52 
Press spacebar to pause and continue. Press esc to stop.